Cargando…

Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis

Detalles Bibliográficos
Autores principales:	Fakhouri, Walid, Sapin, Christophe, Holzkaemper, Thorsten, de la Torre, Inmaculada
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107070/ https://www.ncbi.nlm.nih.gov/pubmed/33742363 http://dx.doi.org/10.1007/s12325-021-01641-w

Ejemplares similares

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis
por: Fautrel, Bruno, et al.
Publicado: (2018)

Authors’ Response to Letter to the Editor Regarding Comparative Efficacy of JAK Inhibitors for Moderate-to-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2021)

Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis
por: Van De Laar, Celine J, et al.
Publicado: (2020)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate
por: Fakhouri, Walid, et al.
Publicado: (2020)

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
por: Schlueter, Max, et al.
Publicado: (2019)

Call for action: incorporating wellness practices into a holistic management plan for rheumatoid arthritis—going beyond treat to target
por: Taylor, Peter C., et al.
Publicado: (2021)

Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
por: Pope, Janet, et al.
Publicado: (2020)

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
por: Taylor, Peter C
Publicado: (2019)

Clinical use of Jak 1 inhibitors for rheumatoid arthritis
por: Nash, Peter
Publicado: (2021)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
por: Boyle, D L, et al.
Publicado: (2015)

Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis
por: Harigai, Masayoshi
Publicado: (2019)

Radiographic progression can still occur in individual patients with low or moderate disease activity in the current treat-to-target paradigm: real-world data from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry
por: ten Klooster, Peter M., et al.
Publicado: (2019)

Letter to the Editor Regarding Vaping Article
por: Spitz, Rabbi Yehuda
Publicado: (2019)

The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis
por: Alten, Rieke, et al.
Publicado: (2022)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis
por: Moura, Rita A., et al.
Publicado: (2021)

Phase III trials of JAK1 selective inhibitors in rheumatoid arthritis
por: Mysler, Eduardo, et al.
Publicado: (2021)

Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis
por: Avci, Ali Berkant, et al.
Publicado: (2021)

Efficacy and Safety of JAK Inhibitors for Rheumatoid Arthritis: A Meta-Analysis
por: Wang, Faping, et al.
Publicado: (2022)

Response letter regarding the letter to the editors by Brown et al.
por: Taylor, Sylvia, et al.
Publicado: (2016)

Letter to the editor: Regarding the editorial by Penttinen and Friede
por: Fry, Alicia M, et al.
Publicado: (2016)

Letter to the Editor Regarding “Letter to the Editor: Spinal and Neurosurgical Publications During the COVID-19 Era”
por: Akhaddar, Ali, et al.
Publicado: (2020)

Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis
por: Pei, Heying, et al.
Publicado: (2018)

JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future
por: Angelini, Jacopo, et al.
Publicado: (2020)

JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data
por: Harrington, Robert, et al.
Publicado: (2020)

Reply to letter to the editor regarding “Use of DPP-4 inhibitors in patients with COVID-19”
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Letter to the Editor Regarding: A Comprehensive Review on Copemyl(®)
por: Comi, Giancarlo, et al.
Publicado: (2018)

Letter to the editor regarding “Rotavirus infection beyond the gut”
por: Orrico-Sánchez, Alejandro, et al.
Publicado: (2019)

Letter to the Editor: Regarding “The Role of Obesity in Pediatric Orthopedics”
por: Rehm, Andreas, et al.
Publicado: (2020)

Letter to the editor regarding the paper “Tick infestation of the eyelid”
por: Dantas-Torres, Filipe
Publicado: (2020)

Letter to the Editor: Regarding COVID-19 in Children with Asthma
por: Özdemir, Öner
Publicado: (2021)

Letter to the editor regarding the article of Chen et al.
por: Islamoglu, Mehmet Sami, et al.
Publicado: (2022)

Letter to the Editor Regarding “Ultrasound Features of Adhesive Capsulitis”
por: Boudier-Revéret, Mathieu, et al.
Publicado: (2022)

Letter to the editor regarding “Selfies: A boon or bane?”
por: Kazerooni, Rashid
Publicado: (2022)

Letter to the Editor Regarding: Evolving Business Models in Orthotics
por: Laakso, L.
Publicado: (2022)

Letter to the editor regarding “unusual extraneural metastasis of glioblastoma”
por: Waack, Andrew Leland, et al.
Publicado: (2023)

Letter to Editor regarding “Unusual Presentation of Spontaneous Chylothorax”
por: Varghese, Anjali Rachel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f03k66f49eckihd2vebdeghm71